Alkermes Healthcare News

This is selected healthcare news for Alkermes, which is filed under Capital Firms. There are 567 news items for this page. Alkermes is occasionally combined with Acorda Therapeutics, Genzyme and AI Therapeutics in news items. A press release filter page is also available for Alkermes.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
12/6/2022 Albireo Appoints Paul Streck, M.D., as Chief Medical
Ai Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise ‚Ai Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings significant global drug development and commercialization expertise ‚Ai Two appointments strengthen Company's ability to scale ...
Globe Newswire
12/6/2022 Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors
Albireo Appoints Paul Streck, M.D., as Chief Medical Officer & Craig Hopkinson, M.D., to Board of Directors ‚Ai Dr. Craig Hopkinson, currently EVP of Research & Development and Chief Medical Officer at Alkermes, brings strong global orphan drug development expertise ‚Ai Dr. Paul Streck, former Chief Medical Officer at Arena Pharmaceuticals, brings ...
healthtechnologynet.com
12/5/2022 The Newport Daily Express
... venture partner at 5AM Ventures and as chief medical officer at Expansion Therapeutics, a 5AM Ventures portfolio company. Dr. Ehrich previously spent 17 years at Alkermes, leading the development and successful FDA registration of multiple new medicines as chief medical officer and executive vice president of R&D. Prior to ...
newportvermontdailyexpress.com
12/2/2022 Alkermes Celebrates Giving Tuesday With Volunteering Efforts
Now Reading Published 2 hours ago Submitted by Alkermes This Giving Tuesday, we are thankful for the employees who take time to support people in our communities who are in need. 10+ years ago, we launched Alkermes in Action, an annual employee volunteer program designed to support volunteer efforts in ...
csrwire.com
12/2/2022 An analyst sees good growth prospects for Alkermes plc (ALKS)
Alkermes plc (NASDAQ: ALKS) stock jumped 1.69% on Thursday to $25.20 against a previous-day closing price of $24.78. With 1.16 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.7 million shares. During the session, the Biotechnology company that operates in wider ...
setenews.com
12/1/2022 Ohio Alkermes Site Named Among Healthiest Employers in the State
Now Reading Published an hour ago Submitted by Alkermes Our Wilmington, Ohio site was named to the 2022 Healthiest Employers of Ohio list! We are proud to receive this award that reflects our commitment to our employees‚Ao well-being and ensuring Alkermes is a great place to work. About ...
csrwire.com
11/30/2022 Head and Neck Cancer pipeline analysis, FDA Approved drugs, Molecule type, Clinical trials and Emerging therapies by DelveInsight | Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche
... GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA, IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech, Purple Biotech, Novartis Oncology, Macrogenics ...
jammujournal.com
11/30/2022 Ohio Alkermes Site Named Among Healthiest Employers in the State
... prestigious ranking We help organizations share their ESG communications with audiences around the world Learn how private equity firms can effectively communicate ESG progress NEWSROOM: Alkermes CAMPAIGN: Alkermes: Corporate Responsibility CONTENT: Multimedia with summary Our Wilmington, Ohio site was named to the 2022 Healthiest Employers of Ohio list! We are ...
3blmedia.com
11/30/2022 Alkermes to Participate in the BofA Securities 2022 Biotech SMID Cap Conference
DUBLIN , Nov. 30, Alkermes plc (Nasdaq: ALKS ) announced today that management will participate in a fireside chat as part of the BofA Securities 2022 Biotech SMID Cap Conference on Wednesday, Dec. 7, 2022 at 8:00 a.m. ET ( 1:00 p.m. GMT ). The live webcast may be accessed under the Investors tab ...
PR Newswire
11/29/2022 Alkermes Supporting Local Communities
Now Reading Published 21 minutes ago Submitted by Alkermes Originally published in Alkermes 2021 Corporate Responsibility Report Alkermes respects the culture, customs and values of the people in the communities in which we operate. We seek to support and positively impact these communities through our grant programs, sponsorship contributions and ...
csrwire.com
11/29/2022 Head and Neck Cancer pipeline analysis, FDA Approved drugs, Molecule type, Clinical trials and Emerging therapies by DelveInsight | Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche
... GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA, IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech, Purple Biotech, Novartis Oncology, Macrogenics ...
abnewswire.com
11/29/2022 Head and Neck Cancer pipeline analysis, FDA Approved drugs, Molecule type, Clinical trials and Emerging therapies by DelveInsight | Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche
... GeoVax, CytomX Therapeutics, PNP Therapeutics, Galectin Therapeutics, Cyteir Therapeutics, Merck KGaA, Boehringer Ingelheim, Transgene, iTeos Therapeutics SA, IntraGel Therapeutics, Incyte Corporation, Cue Biopharma, Rubius Therapeutics, Alkermes, Corregene Biotechnology, NanoCarrier, Kura Oncology, Betta Pharmaceuticals, Arcus Biosciences, Taiho Pharmaceutical, Astex Pharmaceuticals, Bayer HealthCare, Roche, Vaccinex, Pfizer, BioNTech, Purple Biotech, Novartis Oncology, Macrogenics ...
illinoisnewsdesk.com
11/29/2022 AstraZeneca expands oncology portfolio with $320M deal for Neogene Therapeutics
... market is expected to grow at a compounded annual growth rate of 20.7% from 2022 to 2028. Other pharma companies see opportunities in oncology, notably Alkermes, which announced earlier this month that it would separate its commercial-stage neuroscience business from its oncology unit as part of an ongoing review ...
mmm-online.com
11/29/2022 Multiple Sclerosis Market in the 7mm was found to be USD 22,381 million in 2020
... Major players NeuroVax (Immune Response BioPharma Inc.), CNM-Au8 (Clene Nanomedicine), Tolebrutinib (SAR442168) (Sanofi), Evobrutinib/M2951 (Merck Healthcare KGaA), Ublituximab (TG Therapeutics, Inc.), ALKS 8700 (Alkermes/Biogen), and Arbaclofen (Arbaclofen ER) (Osmotica Pharmaceutical), and others are being assessed as potential therapies to be available in the market in the coming ...
abnewswire.com
11/28/2022 Alkermes Plc (ALKS) ... InsiderInsights Weekly Report: November 26, 2022
Alkermes is a biopharmaceutical company. Co.'s products include: ARISTADA, which is an extended-release injectable suspension for the treatment of schizophrenia; VIVITROL, which is for the treatment of alcohol dependence and for the prevention of relapse to opioid dependence; INVEGA SUSTENNA/XEPLION, and RISPERDAL CONSTA, which is for the ...
researchpool.com
11/28/2022 Alkermes Supporting Local Communities
NORTHAMPTON, MA / ACCESSWIRE / November 28, 2022 / Alkermes respects the culture, customs and values of the people in the communities in which we operate. We seek to support and positively impact these communities through our grant programs, sponsorship contributions and volunteer support. Sponsorships Alkermes is proud to be part of the ...
Yahoo News
11/28/2022 cheap cialis generic online germany
... has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe Pharma, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra ...
cuelio.com
11/25/2022 Schizophrenia Therapeutic Market Huge Growth in Future Scope 2022-2028 | AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada Inc - Digital Journal
... Downstream Vendors Key Players including, AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Pfizer, Sandoz Canada Inc., Intas Pharmaceuticals, Novartis AG, Otsuka Pharmaceuticals, Alkermes, Allergan (Forest Labs), and Sumitomo Dainippon Pharma There is Multiple Chapter to display the Global Schizophrenia Therapeutic Market some of them As Follow: Chapter ...
digitaljournal.com
11/25/2022 Global Psychedelic Drugs Market Share, Scope, Size : Future Analysis, Investment Feasibility & Industry Trends and Forecast till 2022-2026
... Emmes Company, Klarisana, AstraZeneca, F. Hoffmann-La Roche Ltd, Dr. Reddy's Laboratories Ltd, Takeda Pharmaceutical Company Limited, Pfizer Inc, Mylan N.V. , Merck & Co., Inc, Alkermes, and ALLERGAN among others. Market Analysis and Insights The Psychedelic Drugs Market size is projected to reach USD Million by 2026, from USD Million ...
heraldkeeper.com
11/24/2022 Addiction Treatment Market: Introduction Accordin
... disorder in 2017. Competition Landscape The global addiction treatment market is fragmented in terms of number of players. Key players in the global market include Alkermes plc, Cipla Ltd., GlaxoSmithKline plc, Pfizer, Inc., Mallinckrodt, Hikma Pharmaceuticals PLC, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, and Indivor Plc. Related ...
wapakdailynews.com
11/24/2022 Addiction Treatment Market to Reach a Value of ~US$ 12 Bn by the of 2030 | Transparency Market Research
... disorder in 2017. Competition Landscape The global addiction treatment market is fragmented in terms of number of players. Key players in the global market include Alkermes plc, Cipla Ltd., GlaxoSmithKline plc, Pfizer, Inc., Mallinckrodt, Hikma Pharmaceuticals PLC, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, and Indivor Plc. Related ...
icrowdnewswire.com
11/24/2022 Global Foot Drop Treatment Devices to Grow at a Substantial
... in the Multiple Sclerosis Market include Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, TG Therapeutics, Inc., Apimeds Inc., Bayer HealthCare, Novartis, Biogen, Alkermes, Genentech, and others. Plantar Fasciitis Market "Plantar Fasciitis Market Outlook 2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as ...
Globe Newswire
11/23/2022 Addiction Treatment Market to Reach a Value of ~US$ 12 Bn by the of 2030 | Transparency Market Research
... disorder in 2017. Competition Landscape The global addiction treatment market is fragmented in terms of number of players. Key players in the global market include Alkermes plc, Cipla Ltd., GlaxoSmithKline plc, Pfizer, Inc., Mallinckrodt, Hikma Pharmaceuticals PLC, Orexo AB, Titan Pharmaceuticals, Inc., Teva Pharmaceutical Industries Ltd, and Indivor Plc. Related ...
winslowevanscrocker.com
11/22/2022 The Burden of Obesity Among Adults With Bipolar I Disorder | MedPage Today
bit.ly/3guSVIX My name is Michael Doane. My role at Alkermes is as a health economics and outcomes researcher. And so part of what we try to do is really to ‚A¶ Share this: Twitter Facebook Like this: Like Loading... Related ...
Wordpress.com
11/21/2022 The Burden of Obesity Among Adults With Bipolar I Disorder
... Education Institute Congress . In this exclusive MedPage Today video, lead researcher Michael J. Doane, PhD, the associate director of Health Economics and Outcomes Research at Alkermes, discusses the results of the study . Following is a transcript of his remarks : My name is Michael Doane. My role at Alkermes is as ...
Medpage Today